TVI-AST-008, NCT05685004: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) |
|
|
| Recruiting | 2/3 | 120 | US | TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide, Chemotherapy | TVAX Biomedical | Glioblastoma Multiforme of Brain | 12/26 | 03/27 | | |
| Recruiting | 2 | 16 | US | P140K-MGMT, O6-benzylguanine, BG, Photon Based Radiotherapy, temozolomide, TMZ, Filgrastim, G-CSF,Granulocyte-Colony Stimulating Factor, carmustine, BCNU,bis-chloronitrosourea | Leland Metheny, National Cancer Institute (NCI) | Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma | 06/25 | 12/25 | | |
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma |
|
|
| Active, not recruiting | 2 | 93 | US | IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide | Imvax | Glioblastoma | 01/25 | 07/27 | | |
| Completed | 1 | 10 | US | MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy | Stanton Gerson MD, National Cancer Institute (NCI) | Glioblastoma Multiforme | 12/20 | 09/22 | | |
